Children with long-standing untreated hypothyroidism often experience delayed bone maturation and impaired linear growth, which can persist even after the initiation of therapy. Therefore, it is of interest to review the effects of levothyroxine therapy on bone age (BA) advancement and growth outcomes in children with hypothyroidism. Known data shows that levothyroxine therapy accelerates bone age progression and improves growth velocity and height outcomes. Early and adequate treatment yields the greatest benefits; however, delayed or prolonged untreated disease limits full height recovery. Thus, timely levothyroxine replacement is essential to minimize growth impairment and preserve adult height potential in pediatric hypothyroidism.
Keywords: Hypothyroidism, bone age, growth velocity, height SDS, levothyroxine, pediatric, thyroxine
Bioinformation
Journal Article
English
41960511
Guideline Central and select third party use “cookies” on this website to enhance the user experience.
This technology helps us gather statistical and analytical information to optimize the relevant content for you.
The user also has the option to opt-out which may have an effect on the browsing experience.